BeOne Medicines Ltd
222 hedge funds and large institutions have $7.2B invested in BeOne Medicines Ltd in 2022 Q3 according to their latest regulatory filings, with 26 funds opening new positions, 73 increasing their positions, 78 reducing their positions, and 36 closing their positions.
333% more call options, than puts
Call options by funds: $12.1M | Put options by funds: $2.79M
0% more funds holding in top 10
Funds holding in top 10: 9 → 9 (0)
0.02% less ownership
Funds ownership: 3.99% → 3.97% (-0.02%)
6% less repeat investments, than reductions
Existing positions increased: 73 | Existing positions reduced: 78
5% less funds holding
Funds holding: 234 → 222 (-12)
17% less capital invested
Capital invested by funds: $8.65B → $7.2B (-$1.45B)
28% less first-time investments, than exits
New positions opened: 26 | Existing positions closed: 36
Top Buyers
| 1 |
Primecap Management
Pasadena,
California
|
+$121M |
| 2 |
Temasek Holdings
Singapore
|
+$24.6M |
| 3 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$22.7M |
| 4 |
TCM
Tang Capital Management
San Diego,
California
|
+$18M |
| 5 |
Invesco
Atlanta,
Georgia
|
+$13.8M |
Top Sellers
ONC Hedge Fund Activity: Q3 2022 in Review
222 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in BeOne Medicines Ltd (ONC) for Q3 2022, worth a combined $7.2B — down 17% from $8.65B a quarter earlier.
Sellers outnumbered buyers: 36 funds closed out of ONC and 26 opened new positions — a net loss of 10 holders — while 78 trimmed existing stakes and 73 added.
The largest buyer was Primecap Management, adding an estimated $121M. The largest seller was Fidelity Investments, cutting an estimated $49.2M.
- 222 institutional investors held BeOne Medicines Ltd (ONC) as of Q3 2022, down from 234 in Q2 2022.
- Funds reported $7.2B of BeOne Medicines Ltd stock for Q3 2022, down 17% quarter-over-quarter.
- 26 funds opened new BeOne Medicines Ltd positions in Q3 2022 and 36 closed out, a net change of -10 holders.
- The largest BeOne Medicines Ltd buyer in Q3 2022 was Primecap Management, an estimated $121M added.
- The largest BeOne Medicines Ltd seller in Q3 2022 was Fidelity Investments, an estimated $49.2M sold.
Based on aggregated 13F filings for Q3 2022.